R
Ryan Y. Kim
Researcher at University of California, San Diego
Publications - 24
Citations - 2203
Ryan Y. Kim is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Microvesicles & Brain tumor. The author has an hindex of 12, co-authored 24 publications receiving 1779 citations. Previous affiliations of Ryan Y. Kim include Harvard University & University of California.
Papers
More filters
Journal ArticleDOI
Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies.
TL;DR: The biologic processes that give rise to various types of EVs, including exosomes, microvesicles, retrovirus like particles, and apoptotic bodies are reviewed and clinical pertinence of these EVs to neuro-oncology will also be discussed.
Journal ArticleDOI
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development.
Johnny C. Akers,Valya Ramakrishnan,Ryan Y. Kim,Johan Skog,Ichiro Nakano,Sandeep C. Pingle,Juliya Kalinina,Wei Hua,Santosh Kesari,Ying Mao,Xandra O. Breakefield,Fred H. Hochberg,Erwin G. Van Meir,Bob S. Carter,Clark C. Chen +14 more
TL;DR: It is demonstrated that the reference transcripts commonly used for quantitative PCR were unreliable for assessing EV miRNA and suggested that CSF EV mi RNA analysis of miR-21 may serve as a platform for glioblastoma biomarker development.
Journal ArticleDOI
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity.
Nadiya M. Teplyuk,Brit Mollenhauer,Galina Gabriely,Alf Giese,Ella Kim,Michael Smolsky,Ryan Y. Kim,Marlon Garzo Saria,Sandra Pastorino,Santosh Kesari,Anna M. Krichevsky +10 more
TL;DR: This study demonstrates that microRNA-based detection of brain malignancies can be reliably performed and that microRNAs in CSF can serve as biomarkers of treatment response in brain cancers.
Journal ArticleDOI
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
Lisa Doherty,Debra C. Gigas,Santosh Kesari,Jan Drappatz,Ryan Y. Kim,J. Zimmerman,Louis Ostrowsky,Patrick Y. Wen +7 more
TL;DR: Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus, and the regimens were reasonably well tolerated.
Journal ArticleDOI
Detection of wild-Type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients
Javier M. Figueroa,Johan Karl Olov Skog,Johnny C. Akers,Hongying Li,Ricardo J. Komotar,Randy L. Jensen,Florian Ringel,Isaac Yang,Steven N. Kalkanis,Reid Thompson,Lori LoGuidice,Emily Berghoff,Andrew T. Parsa,Linda M. Liau,William T. Curry,Daniel P. Cahill,Chetan Bettegowda,Frederick F. Lang,E. Antonio Chiocca,John W. Henson,Ryan Y. Kim,Xandra O. Breakefield,Clark C. Chen,Karen Messer,Fred H. Hochberg,Bob S. Carter +25 more
TL;DR: The high specificity of the CSF-derived EV diagnostic test gives us an accurate determination of positive EGFRvIII tumor status and is essentially a less invasive "liquid biopsy" that might direct mutation-specific therapies for GBMs.